Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Study
Palisade Bio announced the first patient has been dosed in its global Phase 2b Ascentra-UC study of once-daily oral Pali-2108 for ulcerative colitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Study
The company said the global study is evaluating once-daily oral PALI-2108 for ulcerative colitis.
Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Trial
Palisade Bio said the first patient has been dosed in its global ASCENTRA-UC study evaluating once-daily oral PALI-2108 for ulcerative colitis.
Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Study
Palisade Bio says the global ASCENTRA-UC study is evaluating once-daily oral PALI-2108 for ulcerative colitis.
Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Study
Palisade Bio said the global ASCENTRA-UC study is evaluating once-daily oral PALI-2108 for ulcerative colitis.